基线肿瘤免疫浸润对完全切除BRAF V600突变黑色素瘤辅助维莫非尼治疗无病生存的预后影响
BRIM8研究回顾性探索性分析评估完全切除IIC-IIIC期BRAF V600突变黑色素瘤患者接受辅助维莫非尼或安慰剂时基线肿瘤免疫浸润对无病生存(DFS)的影响。结果显示CD8+ T细胞和PD-L1+免疫细胞是DFS有利预后因素,辅助维莫非尼可能克服低CD8+ T细胞或低PD-L1表达相关的不良DFS预后。
要点
- 基线CD8+ T细胞≥1%或PD-L1+免疫细胞≥5%与 placebo 组更长DFS相关。
- 低CD8+ T细胞(<1%)患者从维莫非尼辅助治疗中DFS获益更明显(HR 0.56)。
- 低PD-L1+免疫细胞(<5%)患者从维莫非尼辅助治疗中DFS获益更明显(HR 0.36)。
核心结论
- 肿瘤中心CD8+ T细胞和PD-L1+免疫细胞是完全切除BRAF V600突变黑色素瘤患者DFS的有利预后因素。
- 辅助维莫非尼可能克服低CD8+ T细胞计数或低PD-L1表达相关的不良DFS预后。
研究设计与样本
- BRIM8为III期国际双盲随机安慰剂对照研究,完全切除BRAF V600突变黑色素瘤患者随机接受口服维莫非尼960 mg每日两次或匹配安慰剂52周。
- 本分析为回顾性探索性分析,评估基线肿瘤免疫浸润与DFS的关系。
主要发现
- 在汇总生物标志物人群中,安慰剂组肿瘤中心CD8+ T细胞<1%者中位DFS短于≥1%者(7.7个月 vs 47.8个月)。
- 维莫非尼对比安慰剂的DFS获益在CD8+ T细胞<1%患者中更大(HR 0.56;95%CI 0.34-0.92),在≥1%患者中为HR 0.77(95%CI 0.48-1.22)。
- 安慰剂组肿瘤PD-L1+免疫细胞<5%者中位DFS短于≥5%者(7.2个月 vs 47.8个月)。
- 维莫非尼对比安慰剂的DFS获益在PD-L1+免疫细胞<5%患者中更大(HR 0.36;95%CI 0.24-0.56),在≥5%患者中为HR 0.99(95%CI 0.58-1.69)。
临床怎么用
- 基线肿瘤CD8+ T细胞和PD-L1+免疫细胞检测有助于识别完全切除BRAF V600突变黑色素瘤辅助维莫非尼治疗的潜在获益人群。
- 低CD8+ T细胞或低PD-L1+免疫细胞患者可能从辅助维莫非尼治疗中获得更明显的DFS获益。
局限性
- 本分析为回顾性探索性分析。
- 仅约60%患者肿瘤样本可用于生物标志物分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We conducted a retrospective exploratory analysis to evaluate the effects of baseline tumour immune infiltrate on disease-free survival (DFS) outcomes in patients with fully resected stage IIC-IIIC melanoma receiving adjuvant vemurafenib monotherapy or placebo in the BRIM8 study. PATIENTS AND METHODS: BRIM8 was a phase III, international, double-blind, randomised, placebo-controlled study. Eligible patients with BRAFV600 mutation-positive, completely resected melanoma were randomly assigned to oral vemurafenib (960 mg twice daily) or matching placebo for 52 weeks. The primary end point was DFS. The association of CD8+ T-cell infiltration and programmed death ligand 1 (PD-L1) expression with DFS, as measured by immunohistochemistry, was explored retrospectively. RESULTS: Four hundred ninety-eight patients were randomly assigned to receive adjuvant vemurafenib (n = 250) or placebo (n = 248); tumour samples were available for biomarker analysis for approximately 60% of patients. In the pooled biomarker population, placebo-treated patients with <1% CD8+ T cells in the tumour centre had shorter median DFS than those with ≥1% CD8+ T cells (7.7 versus 47.8 months). DFS benefit from vemurafenib versus placebo was greater in patients with <1% CD8+ T cells [hazard ratio (HR) 0.56; 95% confidence interval (CI) 0.34-0.92) than in patients with ≥1% CD8+ T cells (HR 0.77; 95% CI 0.48-1.22). Likewise, median DFS was shorter among placebo-treated patients with <5% versus ≥5% PD-L1+ immune cells (IC) in the tumour (7.2 versus 47.8 months). A greater DFS benefit with vemurafenib versus placebo was observed in patients with <5% PD-L1+IC (HR 0.36; 95% CI 0.24-0.56) than in patients with ≥5% PD-L1+IC (HR 0.99; 95% CI 0.58-1.69). CONCLUSIONS: The presence of CD8+ T cells and PD-L1+IC are favourable prognostic factors for DFS. Treatment with adjuvant vemurafenib may overcome the poor DFS prognosis associated with low CD8+ T-cell count or PD-L1 expression. CLINICALTRIALS. GOV IDENTIFIER: NCT01667419.
引用
- Ascierto PA, Lewis KD, Di Giacomo AM, et al. Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib. Ann Oncol. 2020. PMID: 31912791. doi:10.1016/j.annonc.2019.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。